HC Wainwright Forecasts Strong Price Appreciation for Astria Therapeutics (NASDAQ:ATXS) Stock

Astria Therapeutics (NASDAQ:ATXS) had its price objective hoisted by research analysts at HC Wainwright from $16.00 to $20.00 in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 167.38% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on the stock. Citigroup reaffirmed an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. JMP Securities increased their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $49.00 target price on shares of Astria Therapeutics in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, Astria Therapeutics has an average rating of “Buy” and an average price target of $30.20.

Astria Therapeutics Stock Performance

NASDAQ:ATXS opened at $7.48 on Wednesday. The stock has a market capitalization of $422.13 million, a P/E ratio of -3.72 and a beta of 0.42. The company has a 50 day moving average price of $6.76 and a 200 day moving average price of $5.75. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.04. Research analysts forecast that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in shares of Astria Therapeutics by 4,607.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock valued at $9,091,000 after purchasing an additional 1,660,039 shares in the last quarter. ADAR1 Capital Management LLC raised its holdings in shares of Astria Therapeutics by 605.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company’s stock valued at $3,427,000 after purchasing an additional 550,706 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Astria Therapeutics by 59.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company’s stock valued at $5,733,000 after purchasing an additional 400,000 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Astria Therapeutics by 8.2% in the 2nd quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company’s stock valued at $24,238,000 after purchasing an additional 342,000 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Astria Therapeutics in the 2nd quarter valued at $1,608,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.